News Headlines Article

Treatment shows promise to slow Alzheimer’s progression
USA Today

An experimental Alzheimer’s drug treatment showed “statistically significant” slowing of cognitive decline in some patients while failing to meet the primary goals of two large studies, Eli Lilly and Co. announced Friday. “We are encouraged by the pooled data that appear to show a slowing of cognitive decline,” said John Lechleiter, Lilly’s chief executive officer, in the statement. “We intend to discuss these data with regulatory authorities to gain their insights on potential next steps.”